Novel agents in development for multidrug-resistant Gram-negative infections: potential new options facing multiple challenges.

Publication/Presentation Date

12-1-2022

Abstract

PURPOSE OF REVIEW: To review novel antiinfective agents in development for multidrug-resistant (MDR) Gram-negative bacterial infections.

RECENT FINDINGS: Four novel agents are in various phases of development (tebipenem, durlobactam-sulbactam, cefepime-taniborbactam, and xeruborbactam). Tebpipenem is an oral carbapenem with a recently completed phase III trial for complicated urinary tract infections while durlobactam-sulbactam represents a potential alternative for drug-resistant Acinetobacter baumannii . Cefepime-taniborbactam possesses in-vitro potency against a range of troubling pathogens and we await further information on a recently completed study on complicated urinary tract infection. Finally, xeruborbactam is an ultrabroad beta-lactamase inhibitor that can be paired with a range of intravenous and oral agents. It exhibits enhanced in-vitro activity against many MDR pathogens, including those resistant to newer, broader spectrum options. Data in humans with xeruborbactam are limited.

SUMMARY: Each of the newer options reviewed possesses a unique range of in-vitro activity against select, challenging pathogens with some narrowly tailored and other broader in activity. Several have both oral and intravenous formulations. Two agents have presented data from recent phase III trials, whereas two are not as advanced in their clinical programs.

Volume

35

Issue

6

First Page

589

Last Page

594

ISSN

1473-6527

Disciplines

Medicine and Health Sciences

PubMedID

36206150

Department(s)

Department of Medicine

Document Type

Article

Link to Full Text

Share

COinS